Literature DB >> 19373863

Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation.

Aruna Turaka1, Gary M Freedman, Tianyu Li, Penny R Anderson, Ramona Swaby, Nicos Nicolaou, Lori Goldstein, Elin R Sigurdson, Richard J Bleicher.   

Abstract

BACKGROUND: We report local recurrence (LR) after breast-conserving surgery and radiation (BCS + RT) for ductal carcinoma in situ (DCIS) to determine outcomes for patients aged <or=40 years compared with older women.
METHODS: The study included 440 women with DCIS treated from 1978 to 2007. All patients received whole-breast radiotherapy with a boost in 95% of cases. Demographics, characteristics, surgical, and adjuvant treatments were analyzed for an effect on LR.
RESULTS: Median age was 56.5 years with 24 patients aged <or=40. Median DCIS size was 0.8 cm. Re-excision was required in 62% of patients, and in 75% of those aged <or=40. Tamoxifen was used in 22%, but only one patient aged <or=40. Median follow-up was 6.8 years. Actuarial LR was 7% (95% confidence interval of 4-11%) at 10 years and 8% (5-14%) at 15 years. There was no difference in LR by age (P = 0.76).
CONCLUSIONS: The long-term risk of LR after BCS + RT for DCIS is low, even in patients <or=40 years. This may be due to patient selection for small size, high utilization of re-excision, and radiation boost. Young age may be a smaller contributor to LR risk in DCIS than previously suggested. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19373863      PMCID: PMC2945304          DOI: 10.1002/jso.21284

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  40 in total

1.  Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy.

Authors:  F A Vicini; L L Kestin; N S Goldstein; P Y Chen; J Pettinga; R C Frazier; A A Martinez
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

2.  Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey.

Authors:  Alphonse Taghian; Majid Mohiuddin; Reshma Jagsi; Saveli Goldberg; Elizabeth Ceilley; Simon Powell
Journal:  Ann Surg       Date:  2005-04       Impact factor: 12.969

3.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Authors:  N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma.

Authors:  M Morrow; J White; J Moughan; J Owen; T Pajack; J Sylvester; J F Wilson; D Winchester
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

5.  Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age.

Authors:  K J Van Zee; L Liberman; B Samli; K N Tran; B McCormick; J A Petrek; P P Rosen; P I Borgen
Journal:  Cancer       Date:  1999-11-01       Impact factor: 6.860

Review 6.  The diagnosis and management of ductal carcinoma in-situ of the breast.

Authors:  D P Winchester; J M Jeske; R A Goldschmidt
Journal:  CA Cancer J Clin       Date:  2000 May-Jun       Impact factor: 508.702

7.  Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status.

Authors:  L J Solin; A Fourquet; F A Vicini; B Haffty; M Taylor; B McCormick; M McNeese; L J Pierce; C Landmann; I A Olivotto; J Borger; J Kim; A de la Rochefordiere; D J Schultz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-15       Impact factor: 7.038

8.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

Authors:  B Fisher; J Dignam; N Wolmark; D L Wickerham; E R Fisher; E Mamounas; R Smith; M Begovic; N V Dimitrov; R G Margolese; C G Kardinal; M T Kavanah; L Fehrenbacher; R H Oishi
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

Review 9.  259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.

Authors:  Salomone Di Saverio; Fausto Catena; Donatella Santini; Luca Ansaloni; Tommaso Fogacci; Stefano Mignani; Antonio Leone; Filippo Gazzotti; Stefano Gagliardi; Angelo De Cataldis; Mario Taffurelli
Journal:  Breast Cancer Res Treat       Date:  2007-08-09       Impact factor: 4.872

10.  Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.

Authors:  N Bijker; J L Peterse; L Duchateau; E C Robanus-Maandag; C A Bosch; C Duval; S Pilotti; M J van de Vijver
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

View more
  7 in total

Review 1.  Network meta-analysis of margin threshold for women with ductal carcinoma in situ.

Authors:  Shi-Yi Wang; Haitao Chu; Tatyana Shamliyan; Hawre Jalal; Karen M Kuntz; Robert L Kane; Beth A Virnig
Journal:  J Natl Cancer Inst       Date:  2012-03-22       Impact factor: 13.506

2.  Biology, treatment, and outcome in very young and older women with DCIS.

Authors:  Rosalinda Alvarado; Sara A Lari; Robert E Roses; Benjamin D Smith; Wei Yang; Elizabeth A Mittendorf; Banu K Arun; Anthony Lucci; Gildy V Babiera; Jamie L Wagner; Abigail S Caudle; Funda Meric-Bernstam; Rosa F Hwang; Isabelle Bedrosian; Kelly K Hunt; Henry M Kuerer
Journal:  Ann Surg Oncol       Date:  2012-05-24       Impact factor: 5.344

3.  Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ.

Authors:  Laura C Collins; Ninah Achacoso; Reina Haque; Larissa Nekhlyudov; Suzanne W Fletcher; Charles P Quesenberry; Stuart J Schnitt; Laurel A Habel
Journal:  Breast Cancer Res Treat       Date:  2013-04-27       Impact factor: 4.872

4.  Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.

Authors:  Audree B Tadros; Benjamin D Smith; Yu Shen; Heather Lin; Savitri Krishnamurthy; Anthony Lucci; Carlos H Barcenas; Rosa F Hwang; Gaiane Rauch; Lumarie Santiago; Eric A Strom; Sarah M DeSnyder; Wei T Yang; Dalliah M Black; Constance T Albarracin; Mariana Chavez-MacGregor; Kelly K Hunt; Henry M Kuerer
Journal:  Ann Surg       Date:  2019-01       Impact factor: 12.969

Review 5.  Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Authors:  Tatyana Shamliyan; Shi-Yi Wang; Beth A Virnig; Todd M Tuttle; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

Review 6.  The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis.

Authors:  M Luke Marinovich; Lamiae Azizi; Petra Macaskill; Les Irwig; Monica Morrow; Lawrence J Solin; Nehmat Houssami
Journal:  Ann Surg Oncol       Date:  2016-08-15       Impact factor: 5.344

7.  Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients.

Authors:  Laura C Collins; Ninah Achacoso; Larissa Nekhlyudov; Suzanne W Fletcher; Reina Haque; Charles P Quesenberry; Balaram Puligandla; Najeeb S Alshak; Lynn C Goldstein; Allen M Gown; Stuart J Schnitt; Laurel A Habel
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.